QIAGEN N.V.’s QGEN fourth-quarter performance was driven by solid potential in molecular diagnostics. The company continues to progress with its test menu expansion, building a solid foundation to ...

The QuantiFERON test delivered another quarter of sales above $100 million, supported by robust demand in all regions. The company sees strong growth opportunities for QuantiFERON, as only 40% of ...

The aim of the present work was to evaluate the usefulness of the interferon-gamma release assays (IGRAs): QuantiFERON-tuberculosis (TB) Gold-In-Tube test (QFG) and T-SPOT.TB for the diagnosis of ...

For more information, contact [email protected]. All ELI students from a country that has been identified as high-risk must be tested for Tuberculosis using the Quantiferon test before coming to ...

Students from countries with a high incidence of TB will be required to have a Quantiferon test as set out in NICE guidelines. Appointments will be arranged by UCL Workplace Health on the first ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...

The patent, among several owned by QIAGEN that protect the QuantiFERON technology, encompasses significant innovations in the QuantiFERON-TB Gold Plus, which is employed worldwide for tuberculosis ...

MARCY L'ÉTOILE, France, March 18, 2025 /PRNewswire/ -- bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration ...